文献速递治疗药物监测与药物基因组学特殊人群用药

胸腔器官移植早期他克莫司游离血浆、总血浆与全血药代动力学

Unbound Plasma, Total Plasma, and Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation.
PubMed 文献 · Clin Pharmacokinet · 2020-01-01

该研究在30例心脏和肺移植受者术后早期用LC-MS/MS测定他克莫司全血、总血浆和游离血浆浓度,并采用非线性混合效应模型建模。结果显示血浆浓度不足全血浓度的1%,红细胞结合呈非线性,最大结合容量与血细胞比容成正比。建议监测经血细胞比容校正的全血他克莫司浓度以改善临床结局。

要点

  • 他克莫司血浆浓度不足全血浓度的1%,红细胞结合率高。
  • 红细胞最大结合容量与血细胞比容成正比,高浓度时分布呈非线性。
  • 临床不稳定胸腔器官移植受者可考虑监测血细胞比容校正的全血浓度。

核心结论

  • 他克莫司与红细胞结合率高,高浓度时分布呈非线性,监测经血细胞比容校正的全血他克莫司浓度可能改善临床不稳定的胸腔器官移植受者的临床结局。

研究设计与样本

  • 研究分析了30例胸腔器官移植受者移植后直接测定的12小时他克莫司全血、总血浆和游离血浆浓度,采用高效液相色谱-串联质谱法测定,并使用非线性混合效应模型进行药代动力学建模。

主要发现

  • 血浆浓度不足全血浓度的1%。
  • 红细胞最大结合容量与血细胞比容成正比,估计为2700 pg/mL(95%CI 1750-3835),解离常数为0.142 pg/mL(95%CI 0.087-0.195)。
  • 结合常数的个体间变异较大,最大结合容量为27%,血浆线性结合常数为29%。

临床怎么用

  • 对于临床不稳定的胸腔器官移植受者,可考虑监测经血细胞比容校正的全血他克莫司浓度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Therapeutic drug monitoring of tacrolimus whole-blood concentrations is standard care in thoracic organ transplantation. Nevertheless, toxicity may appear with alleged therapeutic concentrations possibly related to variability in unbound concentrations. However, pharmacokinetic data on unbound concentrations are not available. The objective of this study was to quantify the pharmacokinetics of whole-blood, total, and unbound plasma tacrolimus in patients early after heart and lung transplantation. METHODS: Twelve-hour tacrolimus whole-blood, total, and unbound plasma concentrations of 30 thoracic organ recipients were analyzed with high-performance liquid chromatography-tandem mass spectrometry directly after transplantation. Pharmacokinetic modeling was performed using non-linear mixed-effects modeling. RESULTS: Plasma concentration was < 1% of the whole-blood concentration. Maximum binding capacity of erythrocytes was directly proportional to hematocrit and estimated at 2700 pg/mL (95% confidence interval 1750-3835) with a dissociation constant of 0.142 pg/mL (95% confidence interval 0.087-0.195). The inter-individual variability in the binding constants was considerable (27% maximum binding capacity, and 29% for the linear binding constant of plasma). CONCLUSIONS: Tacrolimus association with erythrocytes was high and suggested a non-linear distribution at high concentrations. Monitoring hematocrit-corrected whole-blood tacrolimus concentrations might improve clinical outcomes in clinically unstable thoracic organ transplants. CLINICAL TRIAL REGISTRATION: NTR 3912/EudraCT 2012-001909-24.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Sikma MA, Van Maarseveen EM, Hunault CC, et al. Unbound Plasma, Total Plasma, and Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation. Clin Pharmacokinet. 2020. PMID: 31840222. doi:10.1007/s40262-019-00854-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。